Testing effectiveness (Phase 2)Ended earlyNCT03640481
What this trial is testing
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
Who this might be right for
Chronic Graft-versus-host-disease
Kadmon, a Sanofi Company 159